In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value.

Evidence

The provision of information and ”management of sentiment” illustrates why assets (e.g., IPRs, licensing, partnerships, etc.) are so important in the valuation of life science firms (cf. product sales); in effect, it is the information about assets and how that information is disseminated, analyzed, and understood that constitutes valuation, and hence value, in the bioeconomy. — Kean Birch, Rethinking Value in the Bio-economy, 106

Categorization

• XREF: This is the core claim of the assetization thesis the reader is studying — assetization displaces commodification as the operative regime of value. — connects to: Life sciences firms may never produce products, so valuation is prospective rather than embodied — Kean Birch, Rethinking Value in the Bio-economy:…, 38; Understanding value requires studying the assets underpinning firm valuation, not commodity production. — Kean Birch, Rethinking Value in the Bio-economy:…, 39; Asset value is constituted by active management within organizations, not by biological properties. — Kean Birch, Rethinking Value in the Bio-economy:…, 47 (+9 more)
• DEFINE: Defines the theoretical move: valuation in the bioeconomy is constituted by information about assets rather than by realized commercial output.

Related

• Value in the bio-economy is managed through asset governance, not product sales. (similarity 0.91)
• Understanding value requires studying the assets underpinning firm valuation, not commodity production. (similarity 0.91)
• Analyzing bio-economy value requires focusing on assets rather than commodities (similarity 0.89)
• Value in the bio-economy is better theorized through assetization than commodification. (similarity 0.88)
• Life sciences firms may never produce products, so valuation is prospective rather than embodied (similarity 0.86)
• Bio-economy valuation practices are not peculiar to that sector. (similarity 0.86)
• Value is constituted by knowledge and practice, not merely hype. (similarity 0.85)
• Asset value is constituted by active management within organizations, not by biological properties. (similarity 0.85)
• Value in the bio-economy is produced through valuation practices, not intrinsic to biological matter. (similarity 0.84)
• Life science firm value is managed through strategic information release. (similarity 0.83)
• Accounting for biological assets reflects chosen methods, not intrinsic biological qualities (similarity 0.82)
• Asset value derives from future earnings rather than intrinsic commodity value (similarity 0.82)
• Capitalization builds the thing being valued at the same time it appraises that thing (similarity 0.81)
• Biotech firms can be valued as strategic acquisitions, not for their revenue (similarity 0.81)
• Value is not inherent in things but achieved through capitalization practices. (similarity 0.81)

Broader Connections

• Bio-economy valuation practices are not peculiar to that sector. #qualifies (0.95) — Kean Birch, Rethinking Value in the Bio-economy, 121
• Value in the bio-economy is better theorized through assetization than commodification. #expands (0.85) — Kean Birch, Rethinking Value in the Bio-economy, 112
• The influencer’s real commodity is content produced from objects’ attention, not the objects themselves #exemplifies (0.80) — Grant Bollmer, Katherine Guinness, The Influencer Factory, 217
• In protection markets reputation is the product itself, not the signal of it #exemplifies (0.75)